Compare VanEck Junior Gold Miners (GDXJ) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Junior Gold Miners vs Organon & Co. Common Stock — how do they compare? VanEck Junior Gold Miners trades at $106.1 (market cap $8.21B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: VanEck Junior Gold Miners is far larger — about 2.3× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while VanEck Junior Gold Miners pays none. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Junior Gold Miners for 41 Days and Organon & Co. Common Stock for 0 Days on average.
| GDXJ | OGN | |
|---|---|---|
Market Cap | $8.21B | $3.62B |
Volume | 2,596,073 | 2,892,999 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $156.19 | $13.81 |
52-Week Low | $87.56 | $5.70 |
Typical Hold Time | 41 Days | 0 Days |
Enterprise Value | — | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GDXJ, the VanEck Junior Gold Miners ETF, trades at $110.63, down 2.03% on the day amid a bearish technical signal from moving averages. Recent news highlights multiple junior mining companies being added to the ETF's index, potentially increasing its diversification and investor interest. Key technical indicators show mixed signals, with oscillators neutral but moving averages and overall signal leaning bearish.
The outlook for GDXJ is influenced by gold price volatility and the performance of its underlying junior mining holdings. Investment opportunities include exposure to gold's potential upside through leveraged junior miners, but risks involve sector-specific volatility, operational challenges of small-cap miners, and broader market sentiment shifts affecting gold prices.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About VanEck Junior Gold Miners
GDXJ provides exposure to small and mid-cap companies in the global gold and silver mining industry. It focuses on 'junior' miners involved in exploration and early production, featuring 2026 leaders like Pan American Silver and Coeur Mining.
Read more on GDXJ →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
